In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Indevus, Pliva co-promote Sanctura in €161.3mm deal

Executive Summary

In a deal potentially worth €161.3mm ($195mm), Indevus Pharmaceuticals has licensed specialty pharmaceuticals company Pliva DD exclusive US co-promotion rights to sell--through Pliva's US subsidiary Odyssey Pharmaceuticals--Sanctura (trospium chloride) to treat overactive bladder (OAB), an urge incontinence disorder.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Co-Promotion
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register